JP2002503703A5 - - Google Patents

Info

Publication number

JP2002503703A5

JP2002503703A5 JP2000532138A JP2000532138A JP2002503703A5 JP 2002503703 A5 JP2002503703 A5 JP 2002503703A5 JP 2000532138 A JP2000532138 A JP 2000532138A JP 2000532138 A JP2000532138 A JP 2000532138A JP 2002503703 A5 JP2002503703 A5 JP 2002503703A5

Authority

JP

Japan

Prior art keywords

cyclosporin

composition

composition according

solvent

spray drying

Prior art date

1999-02-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 description 21
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 17
• 108010036949 Cyclosporine Proteins 0.000 description 17
• 229960001265 ciclosporin Drugs 0.000 description 17
• 229930105110 Cyclosporin A Natural products 0.000 description 16
• 229930182912 cyclosporin Natural products 0.000 description 15
• 238000000034 method Methods 0.000 description 15
• 239000002904 solvent Substances 0.000 description 6
• 238000001694 spray drying Methods 0.000 description 5
• 239000002245 particle Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
• 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 101150048593 Mdmd gene Proteins 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 239000004974 Thermotropic liquid crystal Substances 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
• 238000000235 small-angle X-ray scattering Methods 0.000 description 1